DBV Technologies will participate in the next AAAAI 2022

Montrouge, France, February 22, 2022

DBV Technologies for Participate to come AAAAI 2022 Congress

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced its upcoming participation in the annual scientific meeting of the American Academy of Allergy, Asthma, and Immunology (AAAAI), February 24 – February 28, 2022. Two scientific presentations were accepted, including a clinical poster and a non-clinical poster. DBV will also have a booth in the AAAAI exhibit hall.

Data that will be presented from the non-clinical poster will discuss the effect of specialist allergy care on health care utilization among children with peanut allergy in the United States, suggesting that allergy care was associated with reduced total health care costs and higher rates of epinephrine prescription. . In addition, the clinical poster will present pooled safety data from phase 3 studies of epicutaneous immunotherapy with investigational Viaskin Peanut 250 mcg in children aged 4 to 11 years, after treatment for up to 36 months in children with peanut allergy. These data informed DBV’s understanding of the healthcare ecosystem and the value proposition of Viaskin Peanut in children with food allergies.

“The data we are presenting at AAAAI this year highlights the safety and tolerability potential of epicutaneous immunotherapy and the Viaskin™ platform,” said Dr. Pharis Mohideen, Chief Medical Officer of DBV Technologies. “I am delighted that we are engaging in in-depth discussions about the potential benefits of using the Viaskin™ platform to treat peanut allergy in children and to further our understanding of how the intervention of a allergist may have wider implications in the healthcare system.”

Viaskin™ Peanut (DBV712 250 μg) is the Company’s lead product candidate designed to potentially reduce the risk of allergic reactions in peanut-allergic children aged 4-11 years due to accidental exposure to peanuts. An experimental, non-invasive, once-daily patch, Viaskin Peanut seeks to deliver micrograms of peanut antigen to activate the immune system. Viaskin Peanut is DBV’s innovative approach to epicutaneous immunotherapy (EPIT), a method of delivering biologically active compounds to the immune system through intact skin.

DBV summaries:

Scientist Presentations

Both e-posters will be accompanied by recorded presentations from the authors and will be available upon request at https://annualmeeting.aaaai.org/ beginning Friday, February 25, 2021.

Please note that only registered attendees will be able to access the Poster Room, which is available through the AAAAI Virtual Platform. After the meeting, these presentations will be available on DBV’s website, www.dbv-technologies.com, for those unable to attend.

Effect of specialty allergy care on health care utilization among children with peanut allergy in the United States will be presented by Dr. Matthew J. Greenhawt, MD, Children’s Hospital Colorado, University of Colorado, Aurora, Denver.

  • Abstract number: 120
  • Date: February 26, 2022, 9:45-10:45 a.m.
  • Location: Convention Center, North Building, Lower Level, Hall 4

Pooled Safety Data from Phase 3 Studies of Epicutaneous Immunotherapy for Peanut Allergy in Children 4-11 Years of Age will be presented by Dr. Rachel G. Robison, MD, Vanderbilt University Medical Center, Nashville, Tennessee

  • Abstract number: 097
  • Date: February 26, 2022, 9:45-10:45 a.m.
  • Location: Convention Center, North Building, Lower Level, Hall 4

About DBV Technologies
DBV Technologies is developing Viaskin™, an exclusive research technology platform with broad potential applications in immunotherapy. Viaskin is based on Epicutaneous Immunotherapy, or EPIT™, DBV’s method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company is committed to safely transforming the care of patients with food allergies. DBV’s food allergy programs include ongoing clinical trials of Viaskin Peanut. DBV Technologies has its global headquarters in Montrouge, France and offices in Bagneux, France, and North American operations in Summit, NJ and New York, NY. The ordinary shares of the Company are listed on compartment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and the ADSs of the Company (each representing half of an ordinary share) are listed on the Nasdaq Global Select Market (Mnemo: DBVT) .

Forward-looking statements
This press release may contain forward-looking statements and estimates, including statements regarding the therapeutic potential of Viaskin™ Peanut as a treatment for children with peanut allergy and the potential benefits of EPIT. These forward-looking statements and estimates are neither promises nor guarantees and involve substantial risks and uncertainties. At this stage, the Company’s products have not been authorized for sale in any country. Among the factors that could cause actual results to differ materially from those described or projected herein are the uncertainties generally associated with research and development, clinical trials and related regulatory reviews and approvals, including impact of the COVID-19 pandemic, and whether preclinical data or initial or interim clinical trial results will be predictive of future or final clinical trial results or future trial results. Additionally, the timing of any action by a regulatory entity cannot be guaranteed, particularly in light of the COVID-19 pandemic. A more detailed list and description of such risks, uncertainties and other risks can be found in the Company’s regulatory filings with the French Autorité des marchés financiers, the Company’s Securities and Exchange Commission documents and reports, including in the Company’s Annual Report on Form 20-F for the fiscal year ended December 31, 2019, and the Company’s future filings and reports. Existing and potential investors are cautioned not to place undue reliance on these forward-looking statements and estimates, which speak only as of the date hereof. Except as required by applicable law, DBV Technologies assumes no obligation to update or revise the information contained in this press release.

Investor RContact
Anne Pollack
DBV Technologies
+1 (857) 529-2363
[email protected]

Media Contact
Angela Marcucci
DBV Technologies
+1 (646) 842-2393
[email protected]

Comments are closed.